Dianthus Therapeutics, Inc. (DNTH)
Nasdaq: DNTH · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Who owns Dianthus Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Nov 5, 2025 says.
Directors and officers
12
report now, of 44 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · COMMON STOCK · 14% in May 12, 2025
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Aug 7, 2026 · COMMON STOCK · 7.1% in Aug 7, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 28, 2026 · Common Stock · 5.1% in Apr 27, 2026
Wellington Management Group LLP
SCHEDULE 13G · filed Aug 13, 2026 · Common Stock · 4.8% in May 15, 2026
Fairmount Funds Management LLC
SCHEDULE 13D/A · filed Nov 25, 2025 · Common Stock, $0.001 par value · reported falling below 5%, from 9.9% in Sep 15, 2025
Avidity Partners Management LP
SCHEDULE 13D/A · filed Nov 19, 2025 · Common Stock, $0.001 par value · reported falling below 5%, from 9.9% in Mar 19, 2025
RA Capital Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 6% in Feb 17, 2026
TCG Crossover GP II, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
Octagon Capital Advisors LP
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock, $0.001 par value · reported falling below 5%, from 6.1% in Nov 14, 2025
Sirenia Capital Management LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.3% in May 15, 2026
BCLS Fund III Investments, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 7.5% in Aug 14, 2025
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.95% in Aug 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.9% in Feb 17, 2026
Deep Track Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 Par Value · reported falling below 5%, from 7.34% in Mar 24, 2025
What DNTH reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 21, 2024.
Insider tradesForm 4
75sales
0purchases
75sales on a scheduled plan
8people selling
$82.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 57 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Garcia Marino | CEO AND PRESIDENT | 12 | $28.0M | 12 | 0 | $0 |
| Savitz Ryan | EVP, CFO & CBO | 22 | $25.5M | 22 | 0 | $0 |
| Randhawa Simrat | EVP, Head of R&D | 11 | $15.0M | 11 | 0 | $0 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | 10 | $5.6M | 10 | 0 | $0 |
| Veness Adam M | SVP, General Counsel and Sec. | 5 | $4.6M | 5 | 0 | $0 |
| Soteropoulos Paula | director | 3 | $2.3M | 3 | 0 | $0 |
| Mcgeorge Anne | director | 5 | $800,000 | 5 | 0 | $0 |
| Read Simon | director | 7 | $600,000 | 7 | 0 | $0 |